- Sections :
- Crime & Public Safety
- Restaurants & Food
- Sports
- More
Categories
Research & Science
Various disciplines to be gathered at Waterway Marriott.
Repros Therapeutics Inc. has released a status update for the one year open label extension of its Phase 2 clinical study ZA-203, of Androxal.
The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.
Repros Therapeutics Inc. has announced that it believes enough patients have enrolled in each of its three ongoing Androxal studies to provide statistically meaningful results for each trial.
Lexicon Pharmaceuticals, Inc. plans to move LX1033 forward into a Phase 2 study in patients with IBS-d.
Opexa Therapeutics, Inc. has been selected to present key Tovaxin® data at the upcoming American Academy of Neurology 63rd Annual Meeting in Honolulu, Hawaii Apr. 9-16.
Repros Therapeutics Inc. has completed its internal review of the results obtained for the 1 mg dose from its low dose study of Proellex®.
Lexicon Pharmaceuticals, Inc. has released postive data results from a recently completed clinical trial of it's drug candidate LX4211 for Type 2 diabetes patients.
Opexa Therapeutics, Inc. has completed two separate meetings with the U.S. Food and Drug Administration regarding their planned development program for Tovaxin.
Dr. Arthur T. Sands, President and CEO of Lexicon Pharmaceuticals, will present at the JPMorgan Healthcare Conference in San Francisco on Jan. 10.
Lexicon Pharmaceuticals, Inc. has released top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis.
The US Patent and Trademark office has issued U.S. Patent to Repros Therapeutics, Inc. for Androxal®, the company’s lead program for the treatment of low testosterone in men.
Lexicon Pharmaceuticals, Inc. will hold a conference call on Monday, August 9, 2010 to discuss its clinical development progress and financial results for the quarter of 2010.
Repros Therapeutics Inc. has received IRB approval to commence a low dose Proellex® study.
Opexa Therapeutics, Inc. has been issued two of its key patents by the U.S. Patent and Trademark Office, with a third patent expected to issue later this month based on a received Notice of Allowance.
StemTroniX, Inc., and Power3 Medical Products, Inc. have filed a joint provisional patent application entitled, “Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy.”
Repros Therapeutics Inc. (NasdaqCM:RPRX) recently held a teleconference with the FDA to review the clinical hold status of Proellex®.
Alan Main, Ph.D., Lexicon's Executive V.P. of Pharmaceutical Research, will present at the BIO International Convention in Chicago, Illinois on Wednesday, May 5.
Lexicon Pharmaceuticals, Inc. will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating IBS at Digestive Disease Week 2010 in New Orleans, LA.
